Skip to main content
SpringerLink
Log in

Present and Future Treatment Strategies for Pulmonary Arterial Hypertension

Focus on Phosphodiesterase-5 Inhibitors

  • Review Article
  • Published:
Treatments in Respiratory Medicine

Abstract

Idiopathic pulmonary arterial hypertension (IPAH) is a rare progressive disorder historically associated with mortality in <3 years post-diagnosis. The etiology of PAH is complex, multifactorial, and likely involves the interplay between genetic and environmental factors. These are reviewed with emphasis on the nitric oxide pathway. Use of treatment modalities including vasodilator therapy have resulted in improved symptoms, hemodynamics, and survival in these patients. Vasodilators, including the calcium channel antagonists, prostanoids, and endothelin receptor antagonists, have been used to counteract potential imbalances in vasoactive mediators in PAH patients; all have produced improved long-term symptomatology and hemodynamics. Only the prostanoid epoprostenol has improved survival in IPAH patients. Although these medications have worked well in many patients with PAH, each of them has limitations. The phosphodiesterase-5 (PDE-5) inhibitors are a relatively new form of treatment for PAH. They are designed to potentiate the effects of cyclic guanosine monophosphate, thereby mimicking endogenous nitric oxide within the vasculature. PDE-5 inhibitors are selective pulmonary vasodilators effective in animal models of pulmonary hypertension. The published clinical studies evaluating their use have been small in size to date but appear to demonstrate benefit. The recently completed 12-week randomized placebo-controlled Sildenafil Use in Pulmonary Hypertension (SUPER-1) trial demonstrated improvement in 6-minute walk distance and hemodynamics in patients receiving sildenafil. These data suggest that the PDE-5 inhibitors are effective in treating PAH and that it is likely that their usage will increase over time. The purpose of this review is to present a current view of the pathogenesis and treatment of PAH, with an emphasis on the use of PDE-5 inhibitors in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II

Similar content being viewed by others

References

  1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107(2): 216–23

    PubMed  CAS  Google Scholar 

  2. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115(5): 343–9

    PubMed  Google Scholar 

  3. Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension; 1998 Sep 6–10; Evian, France. Geneva: World Health Organization, 1998

    Google Scholar 

  4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl. S): 5S–12S

    Article  PubMed  Google Scholar 

  5. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121(6): 409–15

    PubMed  CAS  Google Scholar 

  6. Fishman AP. Pulmonary circulation. In: Geiger SR, editor. Handbook of physiology: the respiratory system. Baltimore (MD): Williams & Wilkins, 1985: 93

    Google Scholar 

  7. Kane LB, Loscalzo J. Pulmonary arterial hypertension. In: Creager MA, Dzau VJ, Loscalzo J, editors. Vascular medicine: a companion to Braunwald’s heart disease. 1st ed. Elsevier, 2006: 795-821

  8. Hoeper MM, Galie N, Simmonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1209–16

    Article  PubMed  Google Scholar 

  9. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361(9368): 1533–44

    Article  PubMed  Google Scholar 

  10. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45(3): 173–202

    Article  PubMed  CAS  Google Scholar 

  11. Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension; endothelium. Clin Chest Med 2001; 22(3): 405–18

    Article  PubMed  CAS  Google Scholar 

  12. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat Genet 1997; 15(3): 277–80

    Article  PubMed  CAS  Google Scholar 

  13. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26(1): 81–4

    CAS  Google Scholar 

  14. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20(3): 518–23

    Article  PubMed  CAS  Google Scholar 

  15. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43(12 Suppl. S): 33S–9S

    Article  PubMed  CAS  Google Scholar 

  16. Mandegar M, Fung YCB, Huang W, et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004; 68: 75–103

    Article  PubMed  CAS  Google Scholar 

  17. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 32: 770–5

    Google Scholar 

  18. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–302

    Article  PubMed  CAS  Google Scholar 

  19. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; I(8385): 1046–7

    Article  Google Scholar 

  20. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782–4

    Article  PubMed  CAS  Google Scholar 

  21. Arnal JF, Dinh-Xuan AT, Pueyo M, et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55(8–9): 1078–87

    Article  PubMed  CAS  Google Scholar 

  22. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151 (2 Pt 1): 384–9

    PubMed  CAS  Google Scholar 

  23. Channick RN, Rubin LJ. Combination therapy for pulmonary hypertension: a glimpse into the future? Crit Care Med 2000; 28(3): 896–7

    Article  PubMed  CAS  Google Scholar 

  24. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70(4): 580–7

    Article  PubMed  CAS  Google Scholar 

  25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76–81

    Article  PubMed  CAS  Google Scholar 

  26. Adnot S, Raffestin B, Eddahibi S, et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87(1): 155–62

    Article  PubMed  CAS  Google Scholar 

  27. Warren JB, Maltby NH, MacCormack D, et al. Pulmonary endothelium-derived relaxing factor is impaired in hypoxia. Clin Sci (Lond) 1989; 77(6): 671–6

    CAS  Google Scholar 

  28. Rubin LJ. Calcium channel blockers in primary pulmonary hypertension. Chest 1985; 88(4 Suppl.): 257S–60S

    Article  PubMed  CAS  Google Scholar 

  29. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76(1): 135–41

    Article  PubMed  CAS  Google Scholar 

  30. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl. S): 68S–72S

    Article  PubMed  CAS  Google Scholar 

  31. Klings ES, Farber HW. Current management of primary pulmonary hypertension (review). Drugs 2001; 61: 1945–56

    Article  PubMed  CAS  Google Scholar 

  32. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30(2): 343–9

    Article  PubMed  CAS  Google Scholar 

  33. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Amer Coll Cardiol 2004; 43: 56S–61S

    Article  CAS  Google Scholar 

  34. Simmoneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4

    Google Scholar 

  35. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20(4): 1037–49

    Article  PubMed  CAS  Google Scholar 

  36. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39(9): 1496–502

    Article  PubMed  CAS  Google Scholar 

  37. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(12): 2119–25

    Article  PubMed  CAS  Google Scholar 

  38. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 981–3

    Article  Google Scholar 

  39. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896–903

    Article  PubMed  CAS  Google Scholar 

  40. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169(4): 441–7

    Article  PubMed  Google Scholar 

  41. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121(6): 1860–8

    Article  PubMed  CAS  Google Scholar 

  42. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–56

    Article  PubMed  CAS  Google Scholar 

  43. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000; 80(4): 1337–72

    PubMed  CAS  Google Scholar 

  44. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274(20): 13729–32

    Article  PubMed  CAS  Google Scholar 

  45. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92(9A): 9M–18M

    Article  PubMed  CAS  Google Scholar 

  46. Ghofrani HA, Roswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 6: 1488–96

    Google Scholar 

  47. Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107(25): 3230–5

    Article  PubMed  CAS  Google Scholar 

  48. Roberts Jr JD, Chiche JD, Weimann J, et al. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ Res 2000; 87(2): 140–5

    Article  PubMed  CAS  Google Scholar 

  49. Schermuly RT, Kreisseimeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169(1): 39–45

    Article  PubMed  Google Scholar 

  50. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104(4): 424–8

    Article  PubMed  CAS  Google Scholar 

  51. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125(2): 580–6

    Article  PubMed  CAS  Google Scholar 

  52. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105(20): 2398–403

    Article  PubMed  CAS  Google Scholar 

  53. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360(9337): 895–900

    Article  PubMed  CAS  Google Scholar 

  54. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006; 353: 2148–57

    Article  Google Scholar 

  55. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25(5): 431–6

    Article  PubMed  CAS  Google Scholar 

  56. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108(17): 2066–9

    Article  PubMed  CAS  Google Scholar 

  57. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43(7): 1149–53

    Article  PubMed  CAS  Google Scholar 

  58. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1): 158–64

    Article  PubMed  CAS  Google Scholar 

  59. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123(4): 1293–5

    Article  PubMed  Google Scholar 

  60. Beyer S, Speich R, Fischler M, et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114–8

    PubMed  CAS  Google Scholar 

  61. Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005; 96: 1334–6

    Article  PubMed  CAS  Google Scholar 

  62. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274–80

    Article  PubMed  CAS  Google Scholar 

  63. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372–6

    Article  PubMed  CAS  Google Scholar 

  64. Molina J, Lucero E, Luluaga S, et al. Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 2003; 12(4): 321–3

    Article  PubMed  CAS  Google Scholar 

  65. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15(13): 1747–8

    Article  PubMed  CAS  Google Scholar 

  66. Wong AR, Rasool AH, Abidin NZ, et al. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42: 147–8

    Article  PubMed  Google Scholar 

  67. Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005; 60: 683–7

    Article  PubMed  CAS  Google Scholar 

  68. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005; 130: 445–53

    Article  PubMed  CAS  Google Scholar 

  69. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2003; 36(6): 529–35

    Article  PubMed  CAS  Google Scholar 

  70. Lacassie HJ, Germain AM, Valdes G, et al. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004; 103 (5 Pt 2): 1118–20

    Article  PubMed  Google Scholar 

  71. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167(8): 1139–41

    Article  PubMed  Google Scholar 

  72. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136(7): 515–22

    PubMed  CAS  Google Scholar 

  73. Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55(1): 55–9

    PubMed  Google Scholar 

  74. Boyce EG, Umland EM. Sildenafil citrate: a therapeutic update. Clin Ther 2001; 23: 2–23

    Article  PubMed  CAS  Google Scholar 

  75. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004; 35(2): 165–7

    PubMed  Google Scholar 

  76. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292–7

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

There are no sources of funding or conflicts of interest directly relevant to the preparation or content of this manuscript.

Author information

Authors and Affiliations

  1. The Pulmonary Center, Boston University School of Medicine, 715 Albany Street, Boston, R-304, Massachusetts, 02118, USA

    Laura B. Kane &  Elizabeth S. Klings

Authors
  1. Laura B. Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth S. Klings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth S. Klings.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kane, L.B., Klings, E.S. Present and Future Treatment Strategies for Pulmonary Arterial Hypertension. Treat Respir Med 5, 271–282 (2006). https://doi.org/10.2165/00151829-200605040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200605040-00005

Keywords

Search

Navigation